AMPH vs BMY
As of Sep 20, 2026, Amphastar Pharmaceuticals (AMPH) scores 7.5/10 and Bristol Myers Squibb (BMY) 6.2/10 on AlphaStocks' five-model composite, so AMPH scores higher. BMY trades 29% below its model fair value.
AMPH
Amphastar Pharmaceuticals, Inc.
7.5
Strong Buy
$23.60
BMY
BRISTOL MYERS SQUIBB CO
6.2
Consider Buy
$63.03
AMPH vs BMY: Which is the Better Investment?
Amphastar Pharmaceuticals, Inc. (AMPH) scores 7.5/10 while BRISTOL MYERS SQUIBB CO (BMY) scores 6.2/10 on AlphaStocks' composite model. Amphastar Pharmaceuticals, Inc. has the higher composite rating of Strong Buy.
This comparison is algorithmically generated and is not financial advice.
| Metric | AMPH | BMY |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 7.5/10▲ | 6.2/10 |
| Rating | Strong Buy▲ | Consider Buy |
| Price | $23.60 | $63.03 |
| P/E Ratio | — | 18.2 |
| ROE | — | 38.1% |
| Market Cap | $1B | $129B |
| Fair Value | — | $88.73 |
| Dividend Yield | — | 4.3% |
| Sector Rank | #4 of 168▲ | #44 of 168 |
| Model Verdicts | ||
| Piotroski | Attractive | Strong▲ |
| Buffett | Attractive | Attractive |
| Graham | Attractive▲ | Caution |
| Lynch | Attractive▲ | Neutral |
| Greenblatt | Attractive | Attractive |
Related comparisons
AMPH vs BMY: Which Stock Scores Higher?
Amphastar Pharmaceuticals, Inc. (AMPH) and BRISTOL MYERS SQUIBB CO (BMY) are both in the Health Care sector. AMPH currently leads with a composite score of 7.5/10 (Strong Buy) compared to BMY's 6.2/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer